Posted by Michael Wonder on 27 Oct 2020
Dracen Pharmaceutical’s DRP-104 granted U.S. FDA fast track designation for the treatment of non-small cell lung cancer
27 October 2020 - Dracen to work closely with FDA to advance the clinical program for the treatment of non-small cell lung cancer with specific mutations.
Dracen Pharmaceuticals announced today that the U.S. FDA has granted fast track designation for the Company’s novel glutamine antagonist DRP-104 for the treatment of advanced, previously treated non-small cell lung cancer patients whose tumours express mutations in KEAP1, NFE2L2 and/or STK11.
